Novel therapeutics for Alzheimer's disease: an update

Curr Opin Drug Discov Devel. 2010 Mar;13(2):235-46.

Abstract

As the most prevalent form of dementia worldwide, Alzheimer's disease (AD) continues to be a burden for patients and their families. In addition, with the global population of aged individuals increasing exponentially, AD represents a significant economic burden to society. The development of an effective approach for the treatment of AD is thus of major importance, as current treatment strategies are limited to agents that attenuate disease symptomatology without addressing the causes of disease. A considerable need exists for the development of an effective therapy to prevent, or at least delay, the progression of AD. Current hypotheses for the pathogenesis of AD are discussed in this review, with a particular emphasis on the implications of these hypotheses with respect to treatment strategies and preventive measures.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Alzheimer Disease / metabolism*
  • Alzheimer Disease / physiopathology
  • Alzheimer Disease / prevention & control*
  • Amyloid beta-Peptides / immunology
  • Animals
  • Antibodies / therapeutic use
  • Antioxidants / pharmacology
  • Antioxidants / therapeutic use
  • Enzyme Inhibitors / therapeutic use
  • Glutamic Acid / metabolism
  • Humans
  • Luteinizing Hormone / metabolism
  • Mitochondria / drug effects
  • tau Proteins / antagonists & inhibitors
  • tau Proteins / drug effects

Substances

  • Amyloid beta-Peptides
  • Antibodies
  • Antioxidants
  • Enzyme Inhibitors
  • tau Proteins
  • Glutamic Acid
  • Luteinizing Hormone